Article
Oncology
Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, Nancy L. DiFronzo, Erica B. Esrick, Joshua J. Field, Courtney D. Fitzhugh, Julie Kanter, Neena Kapoor, Donald B. Kohn, Lakshmanan Krishnamurti, Wendy B. London, Michael A. Pulsipher, Sohel Talib, Alexis A. Thompson, Edmund K. Waller, Ted Wun, Mary M. Horowitz
Summary: This study investigates the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. The results show that the 10-year incidence of leukemia/MDS was 1.7% and of any secondary neoplasm was 2.4%. Low-intensity regimens were associated with higher risks for leukemia/MDS or any secondary neoplasm compared with more intense regimens.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Psychology, Developmental
Marie L. Chardon, Kimberly L. Klages, Naomi E. Joffe, Ahna L. H. Pai
Summary: The study found that families undergoing pediatric hematopoietic stem cell transplant are uniquely prepared to cope with the impacts of a global pandemic.
JOURNAL OF PEDIATRIC PSYCHOLOGY
(2021)
Article
Allergy
Rebecca A. Marsh, Kyle Hebert, Soyoung Kim, Christopher C. Dvorak, Victor M. Aquino, K. Scott Baker, Deepak Chellapandian, Blachy Davila Saldana, Christine N. Duncan, Michael J. Eckrich, George E. Georges, Timothy S. Olson, Michael A. Pulsipher, Shalini Shenoy, Elizabeth Stenger, Mark Vander Lugt, Lolie C. Yu, Andrew R. Gennery, Mary Eapen
Summary: Allogeneic hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis (HLH) disorders is associated with substantial morbidity and mortality. The study found that conditioning regimens using flu/melphalan and flu/melphalan/thiotepa had better outcomes compared to other regimens in terms of post-transplant complications and survival rates in HLH patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Vera Portillo, Stavroula Masouridi-Levrat, Lena Royston, Sabine Yerly, Manuel Schibler, Maria Mappoura, Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Christian van Delden, Yves Chalandon, Dionysios Neofytos
Summary: Positive CMV serology in allogeneic hematopoietic cell transplant recipients (allo-HCTRs) may be false-positive due to transfusion-associated passive immunity. Reclassifying CMV status can help accurately assess the risk of CMV infection in these patients.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Virology
Sebastien Barral, Aline Mamin, Carole Dantin, Stavroula Masouridi-Levrat, Yves Chalandon, Laurent Kaiser, Diem-Lan Vu
Summary: This retrospective observational study found that rhinovirus infections are the most common in allo-HSCT patients, including pre-transplant infections. However, the mortality rate due to pre-transplant RVIs is low.
Review
Hematology
Jacinta Perram, David M. Ross, Donal McLornan, Krisstina Gowin, Nicolas Kroger, Vikas Gupta, Clinton Lewis, Nico Gagelmann, Nada Hamad
Summary: Myelofibrosis is a clonal myeloproliferative neoplasm with limited and ineffective treatment options. The transplantation eligibility criteria for MF patients need to be refined, considering the heterogeneity in disease grade.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Sport Sciences
Melanie Potiaumpai, Stacy Cutrono, Tamia Medina, Maximillian Koeppel, Denise L. Pereira, William F. Pirl, Kevin A. Jacobs, Moataz Eltoukhy, Joseph F. Signorile
Summary: A multidirectional walking program during the transplant period can significantly improve aerobic capacity and quality of life for patients, showing a positive impact on physical function and QOL.
MEDICINE & SCIENCE IN SPORTS & EXERCISE
(2021)
Article
Psychology, Developmental
Marie L. Chardon, Kimberly L. Klages, Naomi E. Joffe, Ahna L. H. Pai
Summary: This study investigated the caregiver-perceived medication facilitators after hematopoietic stem cell transplant (HCT). Through semi-structured qualitative interviews and demographic questionnaires, 29 caregivers of children who had received an HCT within the past 2 years were studied. The findings suggest that caregivers of children after HCT are highly resourceful and develop independent strategies to assist with medication management. However, despite the presence of facilitators and strategies, caregiver burden associated with medication adherence remains high. Therefore, caregivers may benefit from personalized and multicomponent medication adherence supports provided by multidisciplinary treatment teams, particularly shortly after hospital discharge.
JOURNAL OF PEDIATRIC PSYCHOLOGY
(2023)
Article
Microbiology
Philip R. R. Selby, Aaron J. J. Heffernan, David Yeung, Morgyn S. S. Warner, Sandra L. L. Peake, Uwe Hahn, Steven C. C. Wallis, Brett Mcwhinney, Jacobus P. J. Ungerer, Sepehr Shakib, Jason A. A. Roberts
Summary: This study aimed to develop a population pharmacokinetic model for ganciclovir in alloHCT patients and determine dosing regimens to achieve therapeutic exposure targets.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Cell & Tissue Engineering
Le Qi, Misty S. Martin-Sandoval, Salma Merchant, Wen Gu, Matthias Eckhardt, Thomas P. Mathews, Zhiyu Zhao, Michalis Agathocleous, Sean J. Morrison
Summary: The study found that mouse hematopoietic stem cells depend entirely on cell-autonomous aspartate synthesis, which increases upon HSC activation. Aspartate, purine, and asparagine availability limits the function of HSCs during hematopoietic regeneration.
Article
Hematology
Kristin M. Page, Margie A. Ream, Hemalatha G. Rangarajan, Rafael Galindo, Ali Y. Mian, Mai-Lan Ho, James Provenzale, Kathryn E. Gustafson, Jennifer Rubin, Shalini Shenoy, Joanne Kurtzberg
Summary: Infantile Krabbe disease can be effectively treated with hematopoietic cell transplantation if done during the first weeks of life. Newborn screening has facilitated early diagnosis and streamlined treatment referrals for this disease. A retrospective review of six infants diagnosed through newborn screening and treated with hematopoietic cell transplantation showed successful engraftment and improved neurodevelopmental outcomes. All infants are alive and deriving benefits from the timely treatment.
Review
Oncology
Michelle Janssen, Anke Bruns, Juergen Kuball, Reinier Raijmakers, Debbie van Baarle
Summary: This review highlights the importance of vaccination post-stem cell transplantation for patients at risk of infection, emphasizing the significance of timing in order to obtain proper immune response. Individualized approaches may be necessary to optimize vaccine responses, as consensus on optimal timing is currently lacking.
Article
Microbiology
Shiela McCollam, James S. Lewis, Joseph Bubalo, Amber Diaz
Summary: This study aimed to evaluate the efficacy and safety of 300-mg once-monthly intravenous (IV) pentamidine prophylaxis in 702 adult allogeneic hematopoietic stem cell transplant (HSCT) patients. The results showed that IV pentamidine administration effectively prevented Pneumocystis jirovecii pneumonia (PJP), but breakthrough Nocardia and Toxoplasma infections were observed in a certain percentage of patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Gastroenterology & Hepatology
Shaghayegh Habibi, Armin Rashidi
Summary: Disruptions to the gut microbiota have been linked to adverse outcomes after hematopoietic cell transplantation and cellular therapy. Fecal microbiota transplantation (FMT) is a potential therapeutic intervention, but more research is needed before it can be considered a standard treatment. This review examines the evidence for microbiota-outcome associations, highlights the main FMT trials, and suggests future paths for research.
Article
Nutrition & Dietetics
R. Toenges, H. Greinix, A. Lawitschka, J. Halter, A. Baumgartner, A. Simon, J. Arends, P. Jaeger, M. Middeke, I. Hilgendorf, S. Klein, E. M. Wagner-Drouet, C. Schmid, G. Bug, D. Wolff
Summary: The study investigates the clinical practice of nutritional treatment after alloHSCT, revealing variability in nutritional approaches and indicating a need for more high-quality data to support evidence-based nutrition for patients.
CLINICAL NUTRITION
(2021)
Article
Oncology
Seth J. Rotz, Naseer Sangwan, Matthew Nagy, Alice Tzeng, Margaret Jia, Maria Moncaliano, Navneet S. Majhail, Charis Eng
Summary: The intestinal microbiome diversity of long-term survivors of pediatric cancer is reduced, and radiation therapy may further decrease the diversity. The microbiome composition is associated with metabolic syndrome, obesity, and chronic inflammation in these survivors.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2022)
Letter
Biophysics
Sanghee Hong, Lisa Rybicki, Carmelo Gurnari, Simona Pagliuca, Aiwen Zhang, Dawn Thomas, Valeria Visconte, Jibran Durrani, Ronald M. Sobecks, Matt Kalaycio, Aaron T. Gerds, Hetty E. Carraway, Sudipto Mukherjee, Mikkael A. Sekeres, Anjali S. Advani, Navneet S. Majhail, Betty K. Hamilton, Bhumika J. Patel, Jaroslaw P. Maciejewski
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Kripa Shanker Kasudhan, Amol N. Patil, Aditya Jandial, Alka Khadwal, Gaurav Prakash, Arihant Jain, Dinesh Bhurani, Rayaz Ahmed, Narendra Agrawal, Reema Singh, Man Updesh Singh Sachdeva, Neelam Varma, Reena Das, Savita Verma Attri, Samir Malhotra, Navneet S. Majhail, Pankaj Malhotra, Deepesh P. Lad
Summary: This study investigated the pharmacokinetics of cyclophosphamide in haploidentical transplantation and found an association between CEPM AUC(0-48) and severe chronic GVHD and GRFS.
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Kelly J. Gaffney, Theresa A. Urban, Mariana Lucena, Faiz Anwer, Robert M. Dean, Aaron T. Gerds, Betty K. Hamilton, Deepa Jagadeesh, Matt E. Kalaycio, Jack Khouri, Brad Pohlman, Ronald Sobecks, Allison Winter, Lisa Rybicki, Navneet S. Majhail, Brian T. Hill
Summary: Pharmacokinetic-guided therapeutic drug monitoring may be a safe practice in stem cell transplant recipients receiving busulfan conditioning regimens. Most patients in the therapeutic drug monitoring group required dose adjustments and there was no significant difference in toxicity compared to those receiving weight-based dose.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Letter
Biophysics
Agrima Mian, Wei Wei, Betty K. Hamilton, Allison M. Winter, Jack Khouri, Brad Pohlman, Aaron T. Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Paolo F. Caimi, Brian T. Hill, Navneet S. Majhail
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona A. Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson Jr, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji K. Kumar, Saad Z. Usmani
Summary: The use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT), has significantly improved the overall survival (OS) in multiple myeloma (MM) patients. However, the use of lenalidomide maintenance after auto-HSCT has been associated with an increased risk of second primary malignancies (SPM) and second hematological malignancies (SHM). This study evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients after auto-HSCT using registry data.
Article
Hematology
Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan
Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton
Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail
Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Abraham S. Kanate, Navneet Majhail, Zachariah Defilipp, Binod Dhakal, Bhagirathbhai Dholaria, Betty Hamilton, Alex F. Herrera, Yoshihiro Inamoto, Tania Jain, Miguel -Angel Perales, Paul A. Carpenter, Mehdi Hamadani
Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) has published guidelines on CAR-T therapy indications, categorizing them as standard of care and recommending only FDA-approved indications. These guidelines will be periodically updated based on new evidence.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Jeffery J. Auletta, Brenda M. Sandmaier, Erica Jensen, Navneet S. Majhail, Jessica Knutson, Eneida Nemecek, Femina Ajayi-Hackworth, Stella M. Davies
Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) and the National Marrow Donor Program (NMDP) have formed the ACCESS Initiative to address and reduce barriers to hematopoietic cell transplantation (HCT) and cellular therapy (CT) in an effort to ensure equal access and outcomes for all patients. The inaugural workshop discussed goals and provided an initial roadmap for the group's efforts.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Seth J. Rotz, Jean C. Yi, Betty K. Hamilton, Wei Wei, Jaime M. Preussler, Jan Cerny, Abhinav Deol, Heather Jim, Nandita Khera, Theresa Hahn, Shahrukh K. Hashmi, Shernan Holtan, Samantha M. Jaglowski, Alison W. Loren, Joseph McGuirk, Jana Reynolds, Wael Saber, Bipin N. Savani, Patrick Stiff, Joseph Uberti, John R. Wingard, William A. Wood, K. Scott Baker, Navneet S. Majhail, Karen L. Syrjala
Summary: Young adult hematopoietic cell transplantation (HCT) survivors have poorer mental health, increased cancer-related distress, and lower health self-efficacy compared to older adults. Health self-efficacy is strongly associated with health-related quality of life (HRQOL), suggesting that interventions targeting self-efficacy may have a broad impact on health outcomes among young adults.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Nosha Farhadfar, Michael T. Weaver, Zeina Al-Mansour, Jean C. Yi, Heather S. L. Jim, Alison W. Loren, Navneet S. Majhail, Victoria Whalen, Joseph Uberti, John R. Wingard, Debra Lynch Kelly, Karen L. Syrjala
Summary: The self-efficacy level of hematopoietic cell transplantation (HCT) survivors is associated with factors such as fatigue, depression, quality of life, and cancer-related distress. Lower self-efficacy is linked to higher levels of symptoms and distress, as well as lower quality of life. Therefore, improving self-efficacy in survivors is crucial for enhancing their recovery.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Sagar S. Patel, Kwang Woo Ahn, Manoj Khanal, Caitrin Bupp, Mariam Allbee-Johnson, Navneet S. Majhail, Betty K. Hamilton, Seth J. Rotz, Hasan Hashem, Amer Beitinjaneh, Hillard M. Lazarus, Maxwell M. Krem, Tim Prestidge, Neel S. Bhatt, Akshay Sharma, Shahinaz M. Gadalla, Hemant S. Murthy, Larisa Broglie, Taiga Nishihori, Cesar O. Freytes, Gerhard C. Hildebrandt, Usama Gergis, Sachiko Seo, Baldeep Wirk, Marcelo C. Pasquini, Bipin N. Savani, Mohamed L. Sorror, Edward A. Stadtmauer, Saurabh Chhabra
Summary: Noninfectious pulmonary toxicity (NPT) is a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), including idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP). This study found that severe pulmonary comorbidity, acute graft-versus-host disease, mismatched unrelated donor and cord blood transplantation, and HCT Comorbidity Index (HCT-CI) score >= 1 were risk factors for developing NPT, while alloHCT performed in 2014 or later, non-total body irradiation-based conditioning, and platelet recovery were associated with a decreased risk of NPT.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Sanghee Hong, Lisa Rybicki, Linda Mclellan, Jane Dabney, Aaron T. Gerds, Seth J. Rotz, Matt Kalaycio, Rabi Hanna, Betty K. Hamilton, Navneet S. Majhail, Ronald M. Sobecks
Summary: This study compared the HRQOL between haplo-HCT and other donor sources for HCT, showing no difference in some aspects but differences in specific situations. Haplo-HCT demonstrated better emotional and functional well-being in certain conditions.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)